Author: ARCA IT
ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
ARCA BIOPHARMA ANNOUNCES SUBMISSION OF PATENT APPLICATON TO U.S. PATENT AND TRADEMARK OFFICE COVERING TREATMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH HEART FAILURE
ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
GENETIC-AF PHASE 2B TRIAL RESULTS PUBLISHED IN THE JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY: HEART FAILURE
ARCA BIOPHARMA ANNOUNCES STEERING COMMITTEE OF LEADING INTERNATIONAL CARDIOLOGY AND ELECTROPHYSIOLOGY EXPERTS FOR PRECISION-AF PHASE 3 CLINICAL TRIAL
IDENTIFICATION OF PHOSPHODIESTEREASE 3A POLYMORPHISM WITH POTENTIAL TO INCREASE EFFECTIVENESS OF PDE3 INHIBITORS PUBLISHED IN THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
DOSE RESPONSE OF BETA-BLOCKERS IN ADRENERGIC RECEPTOR POLYMORPHISM GENOTYPES PAPER PUBLISHED IN CIRCULATION: GENOMIC AND PRECISION MEDICINE
Beta Blocker Dose Response in AR Polymorphism Genotypes - Circ Genom Precis Med - FINAL